Today we announce W. Brett Graham, MBA, MPA, has been appointed interim CEO for Huntsman Mental Health Institute, and James C. Ashworth, MD, has been appointed interim chair for the...
There may be up to a tenfold difference in risk for infants who are currently treated identically under clinical guidelines. The analysis is an important step toward more personalized pregnancy...
In a recent interview with Dr. Ignacio Garrido-Laguna from the University of Utah Health, we gained fascinating insights into the management of RAS mutations.
An investigational pan-RAS inhibitor—daraxonrasib (RMC-6236)—shows early activity and has a manageable safety profile in patients with previously treated RAS-mutant PDAC, according to data presented at the 2025 ASCO Gastrointestinal Cancers...